A comparison of segmental vs subtotal/total colectomy for colonic Crohn''s disease: a meta-analysis

OBJECTIVE: Using meta-analytical techniques the present study evaluated differences in short-term and long-term outcomes of adult patients with colonic Crohn's disease who underwent either colectomy with ileorectal anastomosis (IRA) or segmental colectomy (SC). METHODS: Comparative studies published between 1988 and 2002, of subtotal/total colectomy and ileorectal anastomosis vs segmental colectomy, were used. The study end points included were surgical and overall recurrence, time to recurrence, postoperative morbidity and incidence of permanent stoma. Random and fixed-effect meta-analytical models were used to evaluate the study outcomes. Sensitivity analysis, funnel plot and meta-regressive techniques were carried out to explain the heterogeneity and selection bias between the studies. RESULTS: Six studies, consisting of a total of 488 patients (223 IRA and 265 SC) were included. Analysis of the data suggested that there was no significant difference between IRA and SC in recurrence of Crohn's disease. Time to recurrence was longer in the IRA group by 4.4 years (95% CI: 3.1-5.8), P < 0.001. There was no difference between the incidence of postoperative complications (OR = 1.4., 95% CI 0.16-12.74) or the need for a permanent stoma between the two groups (OR = 2.75, 95% CI 0.78-9.71). Patients with two or more colonic segments involved were associated with lower re-operation rate in the IRA group, a difference which did not reach statistical significance (P = 0.177). CONCLUSIONS: Both procedures were equally effective as treatment options for colonic Crohn's disease however, patients in the SC group exhibited recurrence earlier than those in the IRA group. The choice of operation is dependent on the extent of colonic disease, with a trend towards better outcomes with IRA for two or more colonic segments involved. Since no prospective randomised study has been undertaken, a clear view about which approach is more suitable for localised colonic Crohn's disease cannot be obtained.     

经胸超声心动图引导与造影引导经皮封堵治疗动脉导管未闭的系统评价与Meta分析

目的比较经胸超声心动图与造影引导经皮封堵治疗动脉导管未闭(PDA)的疗效,为临床应用提供指导。方法计算机检索中国知网、万方、维普、PubMed及Cochrane Library,查找国内外有关经胸超声心动图与造影引导治疗PDA的对照研究,检索时限均从建库至2019年4月,由2位评价员按纳入与排除标准独立筛选文献、提取资料并评价质量后,采用RevMan 5.3软件对所收集的资料进行Meta分析。结果最终纳入8篇中文文献,总样本量为681例。Meta分析结果显示,超声组与造影组的手术成功率差异无统计学意义(RR=0.99,95%CI 0.97~1.01,P=0.40);超声组的术后并发症少于造影组(RR=0.26,95%CI 0.11~0.59,P=0.001)。超声组手术时间(P<0.00001)、术中射线量(P<0.00001)、射线暴露时间(P<0.00001)、住院时间(P<0.00001)、住院费用(P<0.00001)均少或短于造影组,差异有统计学意义。结论与造影引导比较,经胸超声心动图引导经皮封堵治疗PDA是一种创伤小、费用低、安全有效的方法,可代替造影引导作为PDA经皮封堵的引导方式之一。     

腔内治疗逆行撕裂Stanford A型主动脉夹层:Meta分析

目的 采用Meta分析评价腔内治疗逆行撕裂Stanford A型主动脉夹层（RAAD）的效果。方法 检索万方数据库、中国知网及PubMed、Embase、Cochrane library数据库,获得有关腔内治疗RAAD的文献。依据纳入标准筛选文献,采用R软件对文献进行Meta分析,综合评价腔内治疗RAAD围手术期并发症、死亡率及预后。结果 最终纳入11篇文献、共224例RAAD患者。Meta分析结果显示,腔内治疗RAAD围手术期内漏发生率10.22%[95% CI（0.02,0.18）],神经系统并发症发生率0.75%[95% CI（0.00,0.03）],围手术期死亡率1.22%[95% CI（0.00,0.03）]。随访期间6例死亡[0.60%,95% CI（0.00,0.03）],其中5例死因为非主动脉相关性;8例再次接受手术干预[0.89%,95% CI（0.00,0.03）]。结论 腔内治疗RAAD安全、有效。     

发热伴血小板减少综合征患者病死率 及临床特征的Meta 分析

目的 对文献报道的发热伴血小板减少综合征（SFTS）患者的病死率和临床特征进行Meta 分析。 方法 计算机检索PubMed、Embase、The Cochrane Library、CMB、CNKI 和VIP 数据库。选择报告SFTS 临 床特征的无对照观察性研究,摘录有关的信息,使用STATA 11 软件对所选定的数据进行合并。结果 中国地 区21 篇文献共4 320 例,韩国地区3 篇文献共262 例实验室确诊为SFTS 的患者被纳入Meta 分析。中国地区 SFTS 患者合并病死率为16.6%（95% CI ：0.155,0.177）;韩国地区SFTS 患者合并病死率为28.8%（95% CI ： 0.104,0.471）。中国地区SFTS 患者各临床表现的合并阳性率为发热81%（95% CI ：0.680,0.941）、乏力81.3% （95% CI ：0.754,0.872）、血小板减少82.9%（95% CI ：0.713,0.945）、白细胞减少84.9%（95% CI ：0.808, 0.891）、恶心54.2%（95% CI ：0.467,0.617）、厌食77.2%（95% CI ：0.690,0.854）及出血性表现 13.8%（95 CI ： 0.103,0.172）;韩国地区SFTS 患者各临床表现的合并阳性率为发热87.7%（95% CI ：0.810,0.945）、乏力 55.2%（95% CI ：0.180,0.923）、血小板减少88.5%（95% CI ：0.819,0.950）、白细胞减少90.1%（95% CI ： 0.840,0.963）、腹泻50.9%（95% CI：0.285,0.733）及出血性表现23.4%（95% CI：0.041,0.426）。结论 发热、 乏力、血小板减少及白细胞减少为所有SFTS 患者的共同临床表现,中国地区SFTS 患者的胃肠道症状以恶心 及厌食为主要表现,而韩国地区主要以腹泻为主。     

不同重复经颅磁刺激模式对脑卒中后上肢运动功能障碍干预效果的网状Meta分析

背景 上肢运动功能障碍是脑卒中后常见的后遗症之一,严重影响患者日常生活能力。重复经颅磁刺激（rTMS）作为常见的神经电生理技术对治疗脑卒中后上肢运动功能障碍有较好的疗效,但临床对不同rTMS干预模式的选择仍缺乏循证依据。目的 采用网状Meta分析方法比较rTMS的4种模式对脑卒中后上肢运动功能障碍患者的临床疗效。方法 计算机检索PubMed、Embase、Cochrane Library、Web of Science、中国生物医学文献数据库、中国知网、万方数据知识服务平台、维普网中有关rTMS治疗脑卒中后上肢运动功能障碍的随机对照试验,并通过追溯Meta分析的参考文献作为补充。检索时间均为建库至2022年2月,采用主题词和自由词结合方式进行。2名研究者进行文献筛选、资料提取及质量评价。采用RevMan 5.0软件和Stata 16.0软件进行统计学分析。结果 最终纳入17篇文献,790例患者,共涉及6种干预措施：高频rTMS(HF-rTMS)、低频rTMS(LF-rTMS)、间断性theta节律刺激（iTBS）、连续性theta节律刺激（cTBS）、假刺激、常规疗法。网状Meta分析结...     

感染碳青霉烯耐药的肠杆菌科细菌患者全因死亡的Meta分析

目的:评价耐碳青霉烯肠杆菌科细菌感染患者全因死亡风险?方法:检索Pubmed数据库?Embase数据库,并辅以文献追溯?手工检索,检索时间为2001年1月1日至2015年12月31日?纳入同时含有碳青霉烯耐药肠杆科细菌(CRE)及碳青霉烯敏感的肠杆菌细菌(CSE)的临床特征及预后的研究?采用Stata14.0软件进行文献数据进行分析,并评价Meta分析结果的稳定性和发表偏倚?结果:16项研究符合纳入标准,包括2 916例患者(CRE感染797例,CSE 2 119例)?根据纳入研究的设计类型分为队列研究?病例对照研究;根据感染患者细菌检出的标本类型分为血流感染组亚组?综合感染类型亚组(包括尿液?血液?痰等)?队列研究组的CRE感染全因死亡的相对危险度(risk ratio,RR)为2.44(95%CI:1.96~3.03,I2=16.1%,Pheterogeneity=0.312);血流感染亚组的RR为2.07(95%CI:1.59~2.69,I2=0.0%,Pheterogeneity=0.511);综合感染类型亚组的RR为3.35(95%CI:2.25~4.99,I2=0.0%,Pheterogeneity=0.868)?病例对照组的比值比(odds ratio,OR)为2.30(95%CI:1.49~3.55,I2=53.5%,Pheterogeneity=0.018);血流感染亚组的OR为2.85(95%CI:1.66~4.90,I2=60.8%,Pheterogeneity=0.018);综合感染类型亚组的OR为1.46(95%CI:0.73~2.90,I2=25.2%,Pheterogeneity=0.261)?结论:CRE患者病死率明显高于CSE患者,血流感染与患者死亡是密切相关的?     

抗MDA5抗体对成年及幼年型皮肌炎合并间质性肺病诊断效能的meta分析

目的通过meta分析探究抗黑色素瘤分化相关基因5(MDA5)抗体对不同类型皮肌炎(DM)并发快速进展型间质性肺病(RPILD)及慢性间质性肺病(ILD)的诊断效能。方法检索Pub Med、Embase、Cochrane library、中国知网、万方、维普和中国生物医学文献数据库,时间起止为建库至2017年5月。运用Meta-disc1.4行异质性检验,计算汇总敏感度、特异度、诊断比值比、阳性阴性似然比和SROC曲线。采用QUADAS-2和stata 12.0进行质量评价和发表偏倚。结果共纳入32篇研究,文献质量较高,各部分不存在高偏倚风险,为中等异质性。抗MDA5抗体对成年DM合并RPILD的诊断效能(AUC=0.927,Q*=0.862)优于对成年DM合并慢性ILD(AUC=0.717,Q*=0.667)、幼年型皮肌炎(JDM)合并RPILD(AUC=0.836,Q*=0.768)的诊断效能。抗MDA5抗体对DM合并RPILD诊断准确性:临床无肌病型皮肌炎(CADM)(AUC=0.942,Q*=0.880)高于DM(AUC=0.926,Q*=0.860),亚洲(AUC=0.960,Q*=0.891)优于中国(AUC=0.925,Q*=0.859)及欧美人群(AUC=0.928,Q*=0.863),ELISA法(AUC=0.929,Q*=0.864)不劣于免疫沉淀法(AUC=0.927,Q*=0.859)。Deek's漏斗图提示不存在发表偏倚。结论抗MDA5抗体诊断成年及幼年型DM合并ILD有较高敏感性和特异性。     

Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials

To evaluate the efficacy and safety of TNF-α blockers for ulcerative colitis. A systematic search for randomized controlled trials (RCTs) of TNF-α blockers for treatment of ulcerative colitis (UC) were performed in PubMed, Web of Science, Embase and cochrane clinical trial. We estimated Pooled estimates of the odds ratio (OR) and relevant 95% confidence interval (CI) using fixed effects model or random effects model as appropriate. Heterogeneity, publication bias, and subgroup analyses were conducted. Nine randomized controlled studies met the selection criteria with a total of 2518 patients. Five studies compared Infliximab with placebo. Two studies compared Infliximab to corticosteroids. Two studies compared Adalimumab to placebo. One study compared subcutaneous golimumab to placebo. Short-term response, short-term remission, long-term remission and mucosal healing were better in the TNF-α blocker group than in the control group (p < 0.05). TNF-α blockers decreased the colectomy rate and serious adverse reactions (p < 0.05). The TNF-α blockers were superior to controls in achieving short-term clinical response/remission, long-term remission and mucosal healing and decreased the colectomy rate and serious adverse reactions.     

Efficacy and safety of montelukast for pediatric obstructive sleep apnea syndrome: A protocol for systematic review and meta-analysis

Background:Pediatric obstructive sleep apnea syndrome (OSAS) is significant public concern. Clinical practice indicates that montelukast has certain therapeutic advantages, while there is a lack of evidence-based medicine support. The aim of this study is to synthesize related data to explore efficacy and safety of montelukast for pediatric OSAS.Methods:Data in Pubmed, EMBASE, CENTRAL, CBM, CNKI, WanFang, VIP databases were comprehensively searched. All the randomized controlled trials (RCTs) in OSAS children were identified, in which the effects of montelukast on a range of outcomes were compared. The search had a deadline of January 1, 2020. Two investigators independently conducted data extraction and assessed the literature quality of the included studies. The Revman5.3 software was used for meta-analysis of the included literature.Results:The efficacy and safety of montelukast in the treatment of pediatric OSAS were evaluated in terms of apnea hypopnea index (AHI), the Pittsburgh Sleep Quality Index, the Epworth Sleep Scale (ESS), neck circumference, important index in Polysomnography: sleep efficiency, desaturation index, total sleep time.Conclusions:This study provides reliable evidence-based support for the clinical application of montelukast in the treatment of pediatric OSAS.PROSPERO registration number:CRD42020146940.